Board of Directors

Meet the Lobular Breast Cancer Alliance Inc. Board of Directors

The Lobular Breast Cancer Alliance (LBCA) has five board members including the executive director. They are committed to helping LBCA achieve its mission and vision. Their primary duties are: to take care of LBCA by ensuring prudent use of its assets; to ensure, with loyalty to our charity, that LBCA’s activities and transactions and board member decisions are in service to its mission; and to ensure that LBCA adheres to all applicable laws and regulations, as well as its own policies and bylaws. Some board members are individuals who have been directly impacted by invasive lobular carcinoma (ILC). All are deeply caring and dedicated to promoting and helping LBCA fund ILC research, to advance the understanding of ILC, and to identify treatments that are most effective. The board vigorously supports LBCA in striving to change the future for everyone diagnosed with lobular breast cancer.

Tracy Cushing, MD

Tracy Cushing, MD Associate Professor of Emergency Medicine at the University of Colorado, has been a practicing academic physician for 14 years, including teaching residents and medical students. She founded and directed the wilderness and environmental medicine fellowship at CU and was the associate editor of the journal Wilderness and Environmental Medicine. She has participated in designing research projects, grant applications, and has been the section editor for the Wilderness Medical Society clinical practice guidelines for almost 10 years. She was diagnosed with stage 2B ILC in January 2021 and is fully recovered from a double mastectomy without reconstruction and an oophorectomy. She is mom to a 10-year-old girl, a wife, vegan, and recreational triathlete. Her cancer story can be found @tracycrushescancer on Instagram. 

Laurie Hutcheson, Executive Director

Laurie Hutcheson, MS, Executive Director of LBCA, has more than 40 years of experience in health care delivery system development and management including several years in executive roles in Massachusetts health and human services agencies, behavioral health provider organizations, and as a leader and independent consultant in both her own, and other national health care consulting firms. More …

Rachel-Jankowitz-500x500

Rachel C. Jankowitz, MDAssociate Professor of Clinical Medicine in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania and Director of the Rena Rowan Breast Center at the Penn Abramson Cancer Center, has a clinical practice focused on care of patients with breast cancer. Her research has centered around invasive lobular breast cancer (ILC), endocrine resistance in hormone receptor positive breast cancer, and breast cancer clinical trials. She has served as primary investigator and/or co-investigator for many breast cancer clinical trials, and is inactive investigator in the Translational Breast Cancer Research Consortium. Dr. Jankowitz is particularly interested in biomarker development and treatment response in patients with ILC.

Board Member Deb Mueller

Deb Mueller, MD, Professor of Surgery at the University of Texas Health at San Antonio, practices and teaches trauma, surgical critical care, and emergency eurgery. She is a veteran and retired colonel in the US Air Force having served 24 years. During her military service she participated in breast cancer surgical care. Her current academic pursuits are developing leadership training and wellness initiatives for surgical trainees and advocating for women in surgery in regards to specific issues they face. She was diagnosed with stage 2A ILC in January 2022. She is married with two teenage girls and enjoys reading, gardening, hiking, and traveling.

Ramlah Nehring, Ph.D.

Ramlah Nehring, PhD, Head of Strategy and Transactions at Roche Diagnostics. Dr. Nehring is based in San Diego, CA, and leads a global team across APAC, North America and Europe. She has a PhD in Biology from the University of California San Diego and did her graduate studies in molecular genetics at the Salk Institute for Biological Sciences. Ramlah’s professional experience includes the ability to drive strategy and partnerships, with a significant experience in deal sourcing, structuring transactions, leading mergers and acquisitions, and licensing. Prior to working at Roche Diagnostics she led the Corporate Development team at Foundation Medicine. She has spent a significant amount of time in the startup industry in San Diego and has focused her career on improving oncology patient care through access to novel diagnostic solutions. 

Robert Oakes Board of Directors member

Robert OakesCPA, MBA, Senior Principal at Slalom Consulting, focuses on life science clients as they prepare for commercialization of their therapies. Oakes is an experienced business executive and consultant with over 30 years of diverse working experience in consulting, management, accounting, and finance. Prior to working at Slalom, Rob was a director at Integrated Global Performance Solutions and at KPMG Advisory. Before starting his consulting career, Rob served in senior financial management roles in private industry. He started his career in the audit firm of T.M. Byxbee in Albany, NY, before attending graduate school at Bentley College. His combined experience in both consulting and industry brings a unique skill set to his work allowing him to not only understand the latest technology or management theory, but also to understand what does and does not work in practice. His strengths lie in the ability to find creative solutions to complex problems and implement them. His experiences include strategic planning, systems implementation, process improvement, finance transformation, and running enterprise programs. Rob received his BS in Accounting from SUNY Plattsburgh.

Scroll to Top

Join Us

Subscribe for the Latest News & Updates​

  • This field is for validation purposes and should be left unchanged.